Does Teriparatide Reverse Osteonecrosis of the Jaw in Patients with Cancer? A Randomised, Controlled Trial

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1038867

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Osteonecrosis of the jaw (ONJ) is a debilitating bone condition involving damage and suboptimal healing of bone involving the jaw. This has been associated with bisphosphonate therapy, which is commonly used for the treatment of both cancer and osteoporosis. My research aims to investigate the role of recombinant parathyroid hormone in the stimulation of bone formation and healing and, thus, its potential to reverse ONJ.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2015

Funding Scheme: Postgraduate Scholarships

Funding Amount: $137,700.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Endocrinology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

bisphosphonates | bone formation | bone metastasis | bone remodelling | dentistry | endocrinology | myeloma | osteoporosis

Related Links